Correlation Between Molecular Partners and Passage Bio

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Passage Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Passage Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Passage Bio, you can compare the effects of market volatilities on Molecular Partners and Passage Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Passage Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Passage Bio.

Diversification Opportunities for Molecular Partners and Passage Bio

0.4

Correlation Coefficient

Molecular Partners  Passage Bio

Very weak diversification

The 3 months correlation between Molecular and Passage is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Passage Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Passage Bio and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Passage Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Passage Bio has no effect on the direction of Molecular Partners i.e., Molecular Partners and Passage Bio go up and down completely randomly.

Pair Corralation between Molecular Partners and Passage Bio

Given the investment horizon of 90 days Molecular Partners AG is expected to generate 0.43 times more return on investment than Passage Bio. However, Molecular Partners AG is 2.33 times less risky than Passage Bio. It trades about -0.07 of its potential returns per unit of risk. Passage Bio is currently generating about -0.13 per unit of risk. If you would invest  582.00  in Molecular Partners AG on November 29, 2024 and sell it today you would lose (95.00) from holding Molecular Partners AG or give up 16.32% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  Passage Bio

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Passage Bio

Risk-Adjusted Performance

Very Weak

Over the last 90 days Passage Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with Molecular Partners and Passage Bio

The main advantage of trading using opposite Molecular Partners and Passage Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Passage Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Passage Bio will offset losses from the drop in Passage Bio's long position.

The idea behind Molecular Partners AG and Passage Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.